Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
6 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
By Robb M. StewartLifecore Biomedical has agreed to be bought by Webster Equity Partners in a transaction valued at up to $663.7 million.The contract manufacturer of syringes and other injectable pharmaceutical products on Monday said it entered a definitive deal that will see an entity affiliated…
Lifecore Biomedical agreed to be acquired by affiliates of Webster Equity Partners in a take-private transaction that pays shareholders $6.28 in cash per share plus one contingent value right (CVR). The CVR framework includes potential milestone pools of $30 million (2028), $45 million (2029), and…
Lifecore agreed to be acquired by Webster Equity Partners for $6.28 per share in cash plus a non-tradable CVR worth up to $160M, subject to milestones. Closing is expected by end of Q4 2026, pending approvals.Material DetailsContext by AI AnalystThis is a late-stage development culminating in a cha…
CHASKA, Minn. and WALTHAM, Mass., Sept. 28, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. NASDAQ:LFCR today announced that it has entered into a definitive agreement to be acquired by Webster Equity Partners in a transaction valued at up to $663.7 million, assuming full achievement of certain…
Deal value is up to $663.7 million if performance milestones are met; closing is targeted for end-Q4 2026.
Lifecore Biomedical said it will be acquired by Webster Equity Partners.